Targeting HIV-1 env gp140 to LOX-1 elicits immune responses in rhesus macaques

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Zurawski, Gerard ^a,b   Zurawski, Sandra ^a,b   Flamar, Anne Laure ^a,b,n   Richert, Laura ^c   Wagner, Ralf ^d   Tomaras, Georgia D ^e,f   Montefiori, David C ^e,f   Roederer, Mario ^g   Ferrari, Guido ^e   Lacabaratz, Christine ^a   Bonnabau, Henri ^c   Klucar, Peter ^a,b   Wang, Zhiqing ^a,b   Foulds, Kathryn E ^g   Kao, Shing Fen ^g   Yates, Nicole L ^e   LaBranche, Celia ^e   Jacobs, Bertram L ^h   Kibler, Karen ^h   Asbach, Benedikt ^d   Kliche, Alexander ^d   Salazar, Andres ^j   Reed, Steve ^k   Self, Steve ⁱ   Gottardo, Raphael ⁱ   Galmin, Lindsey ^l   Weiss, Deborah ^l   Cristillo, Anthony ^l   Thiebaut, Rodolphe ^c   Pantaleo, Giuseppe ^m   Levy, Yves ^a   more..

^a FACULTÉ DE MÉDECINE   (France)

^b BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^c INSERM   (France)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e DUKE UNIVERSITY   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h ARIZONA STATE UNIVERSITY   (United States)

ⁱ Fred Hutchinson Cancer Research Center   (United States)

^j Oncovir   (United States)

^k INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^l ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^m LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

ⁿ WEILL CORNELL MEDICAL COLLEGE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; GAMMA INTERFERON; GLUCOPYRANOSYL LIPID ADJUVANT; GLYCOPROTEIN GP 140; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 2; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VACCINIA VACCINE; GP140 ENVELOPE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; MONOCLONAL ANTIBODY; OLR1 PROTEIN, HUMAN; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ANTIGENICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CROSS PRESENTATION; CROSS REACTION; CYTOKINE PRODUCTION; DENDRITIC CELL; DIMERIZATION; ENDOTHELIUM CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLUENZA VIRUS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; RHESUS MONKEY; VACCINATION; ANIMAL; ANTIBODY SPECIFICITY; HUMAN; IMMUNOLOGY; MALE; MOUSE; T LYMPHOCYTE;

AIDS VACCINES; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV-1; HUMANS; MACACA MULATTA; MALE; MICE; RECOMBINANT FUSION PROTEINS; SCAVENGER RECEPTORS, CLASS E; T-LYMPHOCYTES;

EID: 84964397371     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153484     Document Type: Article

References (43)

1. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, etal. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012;366:1275-1286. doi:10.1056/NEJMoa1113425 PMID: 22475592
2. Robb ML, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, etal. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAXB/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV144. Lancet Infect Dis 2012;12:531-537. doi:10.1016/S1473-3099 (12) 70088-9 PMID: 22652344
3. Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 2012;30:1-22. doi:10.1146/annurev-immunol-100311-102839 PMID: 22136168
4. Flynn BJ, Kastenmuller K, Wille-Reece U, Tomaras GD, Alam M, Lindsay RW, etal. Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci U S A 2011;108:7131-7136. doi:10.1073/pnas.1103869108 PMID: 21467219
5. Li D, Romain G, Flamar AL, Duluc D, Dullaers M, LI XH, etal. Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. J Exp Med 2012;209:109-121. doi:10.1084/jem.20110399 PMID: 22213806
6. Joo H, Li D, Dullaers M, Kim TW, Duluc D, Upchurch K, etal. C-type lectin-like receptor LOX-1 promotes dendritic cell-mediated class-switched B cell responses. Immunity 2014;41:592-604. doi:10. 1016/j.immuni.2014.09.009 PMID: 25308333
7. Perdiguero B, Gomez CE, Cepeda V, Sanchez-Sampedro L, Garcia-Arriaza J, etal. Virologicaland immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing cladeCtrimeric soluble gp140 (ZM96) and Gag (ZM96)-Pol-Nef (CN54) as virus-like particles. J Virol: 2015;89:970-988. doi:10.1128/JVI.02469-14 PMID: 25355891
8. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, Mejias-Perez E, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006;194:1661-1671. PMID: 17109337
9. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, etal. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N EnglJ Med 2009;361:2209-2220. doi:10.1056/NEJMoa0908492 PMID: 19843557
10. Zolla-Pazner S, de Camp A, Gilbert PB, Williams C, Yates NL, Williams WT, etal. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLOSONE 2014;9:e87572. doi:10.1371/journal.pone.0087572 PMID: 24504509
11. Zolla-Pazner S, Edlefsen PT, Rolland M, Kong XP, de Camp A, Gottardo R, etal. Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses. EBioMedicine 2014;1:37-45. PMID: 25599085
12. Yates NL, Liao HX, Fong Y, de Camp A, Vandergrift NA, Williams WY, etal. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. SciTransl Med 2014;6:228ra239.
13. Tomaras GD, Ferrari G, Shen X, Alam SM, Liao HX, Polara J, etal. Vaccine-induced plasma IgAspecific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A 2013;110:9019-9024. doi:10.1073/pnas.1301456110 PMID: 23661056
14. Vingert B, Perez-Patrigeon S, Jeannin P, Lambotte O, Boufassa F, Lemaître F, et al. HIV controller CD4+ T cells respond to minimal amounts of Gag antigen due to high TCR avidity. PLOS Pathog 2010 6:e1000780.
15. Lin L, Finak G, Ushey K, Seshadri C, Hawn TR, Frahm N, etal. COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat Biotechnol 2015;33:610-616. doi:10.1038/nbt.3187 PMID: 26006008
16. De Rose R, Kent S, Ranasinghe C. Prime-Boost Vaccination: Impact on the HIV-1 Vaccine Field. In: Elsevier MSaMS, editor. Novel Approaches and Strategies for Biologics, Vaccines, and CancerTherapies; 2014.
17. Skinner JA, Zurawski SM, Sugimoto C, Vinet-Oliphant H, Vinod P, Xue Y, etal. Immunologic characterization of a rhesus macaque H1N1 challenge model for candidate influenza virus vaccine assessment. Clin Vaccine Immunol 2014;21:1668-1680. doi:10.1128/CVI.00547-14 PMID: 25298110
18. Epaulard O, Adam L, Poux C, Zurawski G, Salabert N, Rosenbaum P, et al. Macrophage- and neutrophil-derived TNF-alpha instructs skin langerhans cells to prime antiviral immune responses. J Immunol 2014;193:2416-2426. doi:10.4049/jimmunol.1303339 PMID: 25057007
19. Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med 2013;19:1597-1608. doi:10.1038/nm.3409 PMID: 24309663
20. Vaure C, Liu Y. A comparative review of toll-like receptor 4 expression and functionality in different animal species. Front Immunol 2014;5:316. doi:10.3389/fimmu.2014.00316 PMID: 25071777
21. Tewari K, Flynn BJ, Boscardin SB, Kastenmueller K, Salazar AM, Anderson CA, etal. Poly (I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and alphaDEC-CSP in non human primates. Vaccine 2010;28:7256-7266. doi:10.1016/j.vaccine.2010.08.098 PMID: 20846528
22. Park H, Adamson L, Ha T, Mullen K, Hagen SI, Nogueron A, et al. Polyinosinic-polycytidylic acid is the most effective TLR adjuvant for SIV Gag protein-induced T cell responses in nonhuman primates. J Immunol 2013;190:4103-4115. doi:10.4049/jimmunol.1202958 PMID: 23509365
23. Schneider LP, Schoonderwoerd AJ, Moutaftsi M, Howard RF, Reed SG, de Jong EC, etal. Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells. Vaccine 2012;30:4216-4224. doi:10.1016/j.vaccine. 2012.04.051 PMID: 22542815
24. Lumsden JM, Pichyangkul S, Srichairatanakul U, Yongvanitchit K, Limsalakpetch A, Nurmukhambetova S, et al. Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion. Infect Immun 2011;79:3492-3500. doi:10.1128/IAI.05257-11 PMID: 21690242
25. Nkolola JP, Cheung A, Perry JR, Carter D, Reed S, Schuitemaker H, etal. Comparison of multiple adjuvants on the stability and immunogenicity of a cladeC HIV-1 gp140trimer. Vaccine 2014;32:2109-2116. doi:10.1016/j.vaccine.2014.02.001 PMID: 24556505
26. Lewis GK. Challenges of antibody-mediated protection against HIV-1. Expert Rev Vaccines 2010;9:683-687. doi:10.1586/erv. 10.70 PMID: 20624038
27. Mascola JR, Montefiori DC. The role of antibodies in HIV vaccines. Annu Rev Immunol 2010;28:413-444. doi:10.1146/annurev-immunol-030409-101256 PMID: 20192810
28. Garcia-Arriaza J, Perdiguero B, Heeney J, Seaman M, Montifiori DC, Labranche C, etal. Head-to-head comparison of poxvirus NYVAC and ALVAC vectors expressing identical HIV-1 clade C immunogens in prime-boost combination with Env protein in nonhuman primates. J Virol 2015;89:8525-8539. doi:10.1128/JVI.01265-15 PMID: 26041302
29. Flamar AL, Zurawski S, Scholz F, Gayet I, Ni L, Li XH, etal. Non-covalent assembly of anti-dendritic cell antibodies and antigens for evoking immune responses in vitro and in vivo. J Immunol 2012;189:2645-2655. doi:10.4049/jimmunol.1102390 PMID: 22865916
30. Flamar AL, Xue Y, Zurawski SM, Montes M, King B, Sloan L, etal. Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells. AIDS 2013;27:2041-2051. doi:10.1097/QAD.0b013e3283624305 PMID: 23615121
31. Kibler KV, Gomez CE, Perdiguero B, Wong S, Huynh T, Holecheck S, et al. Improved NYVAC-based vaccine vectors. PLOS ONE 2011;6:e25674. doi:10.1371/journal.pone.0025674 PMID: 22096477
32. White SD, Conwell K, Langland JO, Jacobs BL. Use of a negative selectable marker for rapid selection of recombinant vaccinia virus. Biotechniques 2011;50:303-309. doi:10.2144/000113667 PMID: 21548892
33. Montefiori DC. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol 2005; Chapter 12: Unit 12 11. doi:10.1002/0471142735.im1211s64 PMID: 18432938
34. Liao HX, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, Moody MA, etal. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 2013;38:176-186. doi:10.1016/j.immuni.2012.11.011 PMID: 23313589
35. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, etal. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 2008;82:12449-12463. doi:10.1128/JVI.01708-08 PMID: 18842730
36. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, etal. Diversity considerations in HIV-1 vaccine selection. Science 2002;296:2354-2360. PMID: 12089434
37. Liao HX, Sutherland LL, Xia SM, Brock ME, Scearce RM, Vanleeuem S, etal. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 2006;353:268-282. PMID: 17039602
38. Donaldson MM, Kao SF, Eslamizar L, Gee C, Koopman G, Lifton M, et al. Optimization and qualification of an 8-color intracellular cytokine staining assay for quantifying T cell responses in rhesus macaques for pre-clinical vaccine studies. J Immunol Methods 2012;386:10-21. doi:10.1016/j.jim.2012.08.011 PMID: 22955212
39. Foulds KE, Donaldson M, Roederer M. OMIP-005: Quality and phenotype of antigen-responsive rhesus macaque T cells. Cytometry A 2012;81:360-361. doi:10.1002/cyto.a.22008 PMID: 22438313
40. Pollara J, Hart L, Brewer F, Pickeral J, Packard BZ, Hoxie JA, et al. High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A 2011;79:603-612. doi:10.1002/cyto.a.21084 PMID: 21735545
41. Pollara J, Bonsignori M, Moody MA, Liu P, Alam SM, Pinghuang L, etal. HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. J Virol 2014;88:7715-7726. doi:10.1128/JVI.00156-14 PMID: 24807721
42. Edmonds TG, Ding H, Yuan X, Wei Q, Smith KS, Conway JA, et al. Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 2010;408:1-13. doi:10.1016/j.virol.2010.08.028 PMID: 20863545
43. Harari A, Bart PA, Stohr W, Tapia G, Garcia M, Medjitna-Rais E, etal. An HIV-1 cladeC DNA prime, NYVAC boostvaccine regimen induces reliable, polyfunctional, and long-lastingTcell responses. J Exp Med 2008;205:63-77. doi:10.1084/jem.20071331 PMID: 18195071